Qiming Venture Capital has led a US$20 million series A round in Connect Biopharmaceuticals Ltd., a clinical-stage company developing immune modulators for autoimmune diseases and cancer treatment.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?